Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for children with primary malignant brain tumors provide limited
benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it
may prove beneficial in the treatment of children with primary malignant brain tumors.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on children with primary malignant brain tumors.